<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="365100">
  <stage>Registered</stage>
  <submitdate>4/10/2013</submitdate>
  <approvaldate>11/10/2013</approvaldate>
  <actrnumber>ACTRN12613001135707</actrnumber>
  <trial_identification>
    <studytitle>Does genetically guided antidepressant prescribing improve outcomes in depression?</studytitle>
    <scientifictitle>Do adults with major depression whose antidepressant treatment is guided by a pharmacogenetic algorithm generated report have better clinical outcomes compared to care as usual?</scientifictitle>
    <utrn>U1111-1148-7885</utrn>
    <trialacronym />
    <secondaryid>Nil Known</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Major Depression</healthcondition>
    <conditioncode>
      <conditioncode1>Mental Health</conditioncode1>
      <conditioncode2>Depression</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Pharmacogenetic treatment algorithm and report to guide antidepressant dosing.
[1]
a) Patients give a buccal brush sample for DNA analysis of polymorphisms implicated in pharmacokinetic pathways
b) the algorithm provides guidance on the dosing of the antidepressant, type of antidepressant is at clinical discretion
c) any commonly used oral antidepressant currently PBS approved for treatment of major depression can be administered.
d) treatment phase of the study is 12 weeks with daily medication dosing
[2]
Compliance to medication is based on patient report to their prescriber and pharmacy collection of medication.</interventions>
    <comparator>Care as usual - no genetically guided prescribing</comparator>
    <control>Active</control>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Remission from major depression, a score of 7 or less on the 17-item Hamilton Depression Rating Scale</outcome>
      <timepoint>12 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Medication Tolerability. This is assessed by patient report of side effect to their prescriber, and if the side effects is so bothersome to the patient that the prescriber reduced the dose or ceases the antidepressant this will be noted as a medication tolerability problem. Transit or persisting side effects not so bothersome to lead to dose reduction or cessation will not be considered a clinically relevant tolerability issues.</outcome>
      <timepoint>12wks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Principal Diagnosis Major Depression
Requires antidepressant treatment clinically</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Pregnant or Breastfeeding
Conditions where antidepressants contra-indicated
Unable to give informed valid consent</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>1/01/2012</anticipatedstartdate>
    <actualstartdate>24/01/2012</actualstartdate>
    <anticipatedenddate />
    <actualenddate>7/10/2013</actualenddate>
    <samplesize>150</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Closed: follow-up continuing</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Dr Ajeet Singh</primarysponsorname>
    <primarysponsoraddress>PO Box 736, Drysdale Vic, 3222</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname>Dr Ajeet Singh</fundingname>
      <fundingaddress>PO Box 736, Drysdale, Vic 3222</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>To see if a genetic test helps guide antidepressant dosing for better outcomes in depression treatment.</summary>
    <trialwebsite />
    <publication>Data currently in analysis - no poster, oral, or publication based dissemination of the study results/methodology has been conducted.</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname />
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Ajeet B Singh</name>
      <address>PO Box 736, Drysdale Vic 3222
Melbourne University</address>
      <phone>61352487211</phone>
      <fax />
      <email>ajeetsingh@dodo.com.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Ajeet Singh</name>
      <address>Dr Ajeet Singh
The Geelong Clinic
PO Box 9148, St Albans Park Vic 3219</address>
      <phone>+61352487211</phone>
      <fax />
      <email>asingh@dodo.com.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Ajeet Singh</name>
      <address>Dr Ajeet Singh
The Geelong Clinic
PO Box 9148, St Albans Park Vic 3219</address>
      <phone>+61352487211</phone>
      <fax />
      <email>asingh@dodo.com.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>